Flow Neuroscience raises additional Series A funding for at-home tDCS depression treatment
Summary
Flow Neuroscience, a Swedish healthcare technology company, has raised additional funding as part of its ongoing Series A to support FDA approval and US market entry for its at-home transcranial direct current stimulation (tDCS) headset for depression. The Malmö-based company's Flow headset is already commercially available across Europe and the UK, with over 55,000 active users.
Why it matters
Flow Neuroscience achieved FDA approval in early 2026 for the world's first at-home brain stimulation treatment for depression, making it the first tDCS device approved for this indication in the US. The CE-marked device offers a non-pharmaceutical, self-managed alternative for the estimated 20+ million US adults with depression, particularly those who do not respond to medication.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial